Intervention Review

You have free access to this content

Effect of longer-term modest salt reduction on blood pressure

  1. Feng J He1,*,
  2. Jiafu Li2,
  3. Graham A MacGregor1

Editorial Group: Cochrane Hypertension Group

Published Online: 30 APR 2013

Assessed as up-to-date: 28 FEB 2013

DOI: 10.1002/14651858.CD004937.pub2


How to Cite

He FJ, Li J, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD004937. DOI: 10.1002/14651858.CD004937.pub2.

Author Information

  1. 1

    Queen Mary University of London, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, London, UK

  2. 2

    Affiliated Hospital of LuZhou Medical College, Department of Cardiology, Luzhou, Sichuan, China

*Feng J He, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. f.he@qmul.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 30 APR 2013

SEARCH

[Figure 1]
Figure 1. PRISMA  Flow  Diagram
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Funnel plot to explore publication bias (systolic BP). The vertical line is at the mean effect size. Precision is the reciprocal of the standard error of the change in systolic BP.
[Figure 4]
Figure 4. Funnel plot to explore publication bias (diastolic BP). The vertical line is at the mean effect size. Precision is the reciprocal of the standard error of the change in diastolic BP.
[Figure 5]
Figure 5. Cardiovascular disease (CVD) events in a meta-analysis of randomised salt reduction trials using fixed effect model with normotensives and hypertensives combined. TOHP I: Trial of Hypertension Prevention, phase 1. TOHP II: Trial of Hypertension Prevention, phase 2. TONE: Trial of Nonpharmacologic Interventions in Elderly.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Change in BP, Outcome 1 Change in Systolic BP.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Change in BP, Outcome 2 Change in Diastolic BP.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Change in BP, Outcome 3 Change in Systolic BP by Ethnic Group.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Change in BP, Outcome 4 Change in Diastolic BP by Ethnic Group.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Change in BP, Outcome 5 Change in Systolic BP by Sex.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Change in BP, Outcome 6 Change in Diastolic BP by Sex.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Change in hormone & lipid, Outcome 1 Change in PRA.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Change in hormone & lipid, Outcome 2 Change in Aldosterone.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Change in hormone & lipid, Outcome 3 Change in Noradrenaline.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Change in hormone & lipid, Outcome 4 Change in Adrenaline.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Change in hormone & lipid, Outcome 5 Change in Cholesterol.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Change in hormone & lipid, Outcome 6 Change in LDL.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Change in hormone & lipid, Outcome 7 Change in HDL.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Change in hormone & lipid, Outcome 8 Change in Triglyceride.